Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00213980
Status:
COMPLETED
Last Update Posted:
2019-11-27
First Post:
2005-09-13
Brief Title:
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
Sponsor:
University of Wisconsin Madison
Organization:
University of Wisconsin Madison
Study Overview
Official Title:
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
Status:
COMPLETED
Status Verified Date:
2017-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a two arm double-blind randomized study looking at the effect of zoledronate a bisphosphonate on the bone mineral density BMD of postmenopausal women with breast cancer
Detailed Description:
This is a two arm double-blind randomized study looking at the effect of zoledronate a bisphosphonate on the bone mineral density BMD of postmenopausal women with breast cancer An approved bisphosphonate alendronate is of benefit in patients with osteoporosis however this agent has a roughly 30 incidence of gastrointestinal symptoms and up to 50 of patients may take the drug improperly compromising absorption and potentially efficacy Zoledronate is a heterocyclic imidazole third generation bisphosphonate which is administered intravenously IV and has little toxicity Zoledronate is more potent than alendronate and because of its route of administration it does not have the problems of poor oral bioavailability and non-compliance
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SMPHMEDICINEMEDICINEH | OTHER | UW Madison | None |
| A534260 | OTHER | None | None |